{"id":6132,"date":"2026-10-07T07:21:24","date_gmt":"2026-10-07T14:21:24","guid":{"rendered":"https:\/\/www.iths.org\/participate\/?p=6132"},"modified":"2026-10-07T07:21:24","modified_gmt":"2026-10-07T14:21:24","slug":"crps-rise","status":"publish","type":"post","link":"https:\/\/www.iths.org\/participate\/crps-rise\/","title":{"rendered":"CRPS-RISE"},"content":{"rendered":"
<\/div>\n

Why CRPS-RISE?
\nCRPS-RISE (NCT07210515) is a Phase 3 randomized, triple-blind, placebo-controlled clinical trial evaluating neridronate as a potential new treatment option for Complex Regional Pain Syndrome Type 1 (CRPS-1), a rare and debilitating condition with an annual incidence of ~65,0001 and currently no FDA-approved medicine in the United States.<\/p>\n

What\u2019s Involved?
\nStudy-related medical care and treatment provided at no cost
\n10 study visits over a minimum of 14 weeks (screening period may be up to 6 weeks)
\nPatient-Centric Care in Research:
\n\u2022 Travel & accommodation support\/assistance for those who qualify
\n\u2022 Quality of life patient-reported outcomes
\n\u2022 Labs and blood draws \u2013 with some potentially done at home
\n\u2022 An Expanded Access Program and Patient Registry for those completing the trial<\/p>\n

Why Should Patients Participate?
\n– Help advance research for CRPS-1 for future generations
\n– Further the evidence base supporting the use of neridronate in patients with early and warm CRPS-1, with a positive triple phase bone scan
\n– Contribute to a potential new treatment option for CRPS-1
\n– Receive close monitoring and expert care<\/p>\n

Learn more at https:\/\/crps-rise.com\/<\/a><\/p>\n

Participant Eligibility<\/h3>\n

You may be eligible to participate if you:
\n\u2022 Are aged 18 years or older
\n\u2022 Started having symptoms within the last 6 months
\n\u2022 Have CRPS in only one limb and that limb is swollen,
\nred, and\/or warm<\/p>\n

There are other requirements that the trial doctor can
\ndiscuss with you. The investigational drug in this trial is
\nbeing studied specifically for the warm subtype of CRPS-1.
\nThat is why the trial focuses on certain people with CRPS
\nand not everyone.<\/p>\n

Contact<\/h3>\n

Hanna Grioni
\n(206) 807-1430<\/p>\n

<\/p>\n

Additional Study Details<\/h3>\n

Full Study Title<\/strong>
\nA Randomized, Triple-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous AMBTX-01 (Neridronate) for Treatment of Complex Regional Pain Syndrom Type 1 (CRPS-RISE)
\n<\/span><\/p>\n

Study ID:<\/strong> SSU00311243<\/div>\n
ClinicalTrials.gov Link:<\/strong> NCT07210515<\/a><\/div>\n
<\/div>\n
Start Date:<\/strong> 08\/14\/2026<\/div>\n
End Date:<\/strong> 01\/12\/2027<\/div>\n
<\/div>\n

Investigator(s)<\/strong>
\nBrett Stacey, MD
\nYian Chen, MD
\n<\/span>
\nAccepts Healthy Volunteers?<\/strong>
\nNo<\/span><\/p>\n

Study Site(s)<\/strong><\/p>\n

\n

University of Washington<\/h4>\n

1959 NE Pacific St.
\nSeattle, Washington 98195<\/p>\n<\/div>\n

\n

<\/h4>\n<\/div>\n
<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Why CRPS-RISE? CRPS-RISE (NCT07210515) is a Phase 3 randomized, triple-blind, placebo-controlled clinical trial evaluating neridronate as a potential new treatment option for Complex Regional Pain Syndrome Type 1 (CRPS-1), a rare and debilitating condition with an annual incidence of ~65,0001 and currently no FDA-approved medicine…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[19],"tags":[594,39],"class_list":["post-6132","post","type-post","status-publish","format-standard","hentry","category-pain-managementanesthesiology","tag-crps","tag-pain"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/comments?post=6132"}],"version-history":[{"count":2,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6132\/revisions"}],"predecessor-version":[{"id":6134,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/6132\/revisions\/6134"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/media?parent=6132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/categories?post=6132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/tags?post=6132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}